A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir has not been determined. Therefore, we conducted a Phase Ia study to establish the maximum tolerated dose (MTD) and dose limiting toxicities...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Blumenthal, Gideon M., Gills, Joell J., Ballas, Marc S., Bernstein, Wendy B., Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M., LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R., Figg, William D., Dennis, Phillip A.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2014
Assuntos:
Clinical Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226674/
https://ncbi.nlm.nih.gov/pubmed/25327558
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares